Last $4.99 USD
Change Today -0.20 / -3.85%
Volume 1.1M
PGNX On Other Exchanges
As of 5:20 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - $7.45
52 Week Low
05/9/14 - $3.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

69 Employees
Last Reported Date: 03/13/14
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Vice President of Regulatory Affairs
Total Annual Compensation: $341.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGNX) Key Developments

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. Announces FDA Approval of RELISTOR Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. announced that the Food and Drug Administration has approved RELISTOR (methylnaltrexone bromide) Subcutaneous Injection, 12 mg/0.6ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain. RELISTOR subcutaneous injection is currently the only available peripherally acting mu opioid receptor antagonist (PAMORA) that is approved for treating OIC at the cause without interfering with the centrally acting analgesic properties of the opioid. Traditional laxative treatments are often ineffective for many chronic pain patients suffering with opioidinduced constipation. Approximately 80% of chronic pain patients with OIC that were taking laxative therapy continued to report difficulties dealing with their constipation symptoms, as documented by a large patient survey published in 2008 in Pain Medicine. One third of these chronic pain patients reported stopping or lowering their opioid dose in order to relieve their opioid induced constipation, resulting in increased pain levels.

Progenics Pharmaceuticals, Inc. Announces Dr. Hagop Youssoufian Step Down as Executive Vice President, Research and Development

Progenics Pharmaceuticals, Inc. announced that Dr. Hagop Youssoufian stepped down as Executive Vice President, Research and Development of the company to pursue other interests, effective September 19, 2014.

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

Progenics Pharmaceuticals, Inc. presented positive data from a pivotal phase 2 clinical study of Azedra in an oral presentation at the International Symposium of Pheochromocytoma and Paraganglioma (ISP) in Kyoto, Japan. Azedra (Ultratrace(TM) Iobenguane I-131) is Progenics' radio-therapeutic candidate that targets the ultra-orphan diseases pheochromocytoma and paraganglioma. As of June 2014, seven of the enrolled patients have received one and 34 have received two therapeutic doses of Azedra. The study's primary endpoint, a reduction of at least 50% of anti-hypertensive medications for at least six months, was achieved by 31.7% of patients. Patients receiving two therapeutic doses of Azedra had a median survival of 43.3 months as of June; long-term follow-up is continuing. The most common adverse events observed have been gastroenterological and hematologic disorders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $4.99 USD -0.20

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.40 USD -0.02
Dynavax Technologies Corp $1.42 USD -0.01
Peregrine Pharmaceuticals Inc $1.31 USD -0.05
Transgene SA €8.37 EUR -0.33
ZIOPHARM Oncology Inc $2.56 USD -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation PGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.4x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at